LSI Europe

 1. Where can I register for LSI Europe '26? Register for LSI Europe '26 here. You can also apply to present at LSI Europe '26 here. 2. What does my LSI Europe '26 registration include? Registration includes access to all days of the event (September 28 - October 1), all sessions, meals, networking receptions, and the partnering platform. 3. Will meals be provided during the event? Yes. Breakfast, lunch, and dinner will be served on September 29, September 30, October 1 with an additional dinner served on September 28 during the Welcome Reception. 4. Can I register a group of people for Europe Europe '26? Yes. Please contact kelly@ls-intel.com for more details. 5. Can I get a discount for registering for multiple LSI events? Please contact kelly@ls-intel.com for more details. Visit here for more details: https://www.lsieuropesummit.com/faq

We’re proud to partner with the world’s most trusted names in healthcare, investment, and technology. Meet the sponsors powering the LSI Europe Emerging Medtech Summit, including top investors, medtech innovators, and global healthcare partners. Visit here: https://www.lsieuropesummit.com/sponsors

“Sometimes those technologies need to be looked at from the needs perspective. Why would the end customer be willing to adopt it; why would a physician want to change their current practice and standard of care?” said Beatriz Volckaert Almansa, Investment Director at Philips Ventures. Her insight underlines a crucial consideration for investors and entrepreneurs alike: technology alone is not enough; it must align with real-world needs. From the importance of identifying market demand early to structuring strong teams and strategic partnerships, the discussion provided a wealth of actionable insights for medtech innovators looking to navigate the complexities of technology transfer. Originally published at: https://www.lsieuropesummit.com/news/technology-transfer-in-medtech-the-path-to-successful-investments

This Signature took place at LSI Europe ‘25 Emerging Medtech Summit in London. Join industry leaders Roger Brooks, Oern Stuge, and Samuel Levy as they examine the evolution and impact of OrganOx in the organ transplantation field, sharing insights on Terumo's $1.5 billion acquisition of OrganOx. Visit here: https://www.youtube.com/watch?v=Nw9ncVZPhpQ

In the medtech world, a “no” from an investor isn’t always what it seems. The decision to pass on a startup often comes down to more than just the technology—it’s a balancing act of risk, timing, and fit. And for the investors themselves, building a smart portfolio means getting comfortable with saying no—a lot. The Risk-Reward Dance The heart of the conversation revolved around a common challenge: how do medtech investors decide when a startup is worth the risk? Diana shared her experience passing on SIA during its Series A round. Despite FDA 510(k) clearance and a ready-to-launch product, she flagged a lack of clinical data and market validation. “It was all unknown,” she said. “Even though the product was approved, the addressable market size was unclear. That was perceived as a big risk.” Visit here: https://www.yumpu.com/en/document/view/70881036/medtech-portfolio-optimization-why-investors-say-no

And while verbal yeses may feel like validation, they’re not always equal. “ICs [investment committees] will have different thresholds,” Masterson added. “You can end up in a chicken-and-egg scenario, needing to herd a full syndicate into alignment just to move forward.” Post-term sheet diligence is when the real work begins. For entrepreneurs, it’s about managing momentum while under a microscope. For medtech investors, it’s about confirming the deal’s risk profile—beyond the pitch deck. Visit here: https://www.flipgorilla.com/p/29362908924217984/show